Ribo Life Science Marks Major Milestone with Successful IPO on Hong Kong Stock Exchange

Ribo Life Science Achieves Successful Listing on the Hong Kong Stock Exchange

On January 9, 2026, Ribo Life Science Co., Ltd., commonly referred to as Ribo, proudly announced its successful listing on the Main Board of the Hong Kong Stock Exchange under the stock code 06938.HK. This momentous occasion not only symbolizes a significant accomplishment for the company but also represents a pivotal milestone within the biopharmaceutical industry, particularly in the field of small interfering RNA (siRNA) therapeutics.

Ribo's global offering saw the issuance of a total of 31,610,400 shares, priced at HKD 57.97 each, successfully raising gross proceeds exceeding 1.8 billion Hong Kong dollars. The initial public offering (IPO) witnessed overwhelming interest, with over 100 times oversubscription reported for the Hong Kong Public Offering (HKPO) and 16.7 times for the International Placement. These figures reflect a strong and growing confidence among global investors in both the siRNA sector and Ribo's capabilities as an innovator in this space.

In appreciation of this support, Dr. Zicai Liang, Founder, Chairman, and CEO of Ribo, expressed heartfelt gratitude towards global investors, stating, “Listing on the Hong Kong Stock Exchange represents a major milestone in Ribo's journey. We extend our sincere gratitude to global investors for their trust and support.” He further emphasized the firm’s commitment to leveraging international capital markets to expedite the clinical development and commercialization of siRNA therapeutics worldwide.

The funds raised from the IPO will be strategically allocated across several key areas to bolster the company’s future endeavors:
1. Advancing global multicenter clinical trials for core products.
2. Supporting preclinical and clinical pipeline development.
3. Iterating and upgrading siRNA delivery and related technology platforms.
4. Replenishing operational capital to ensure ongoing corporate objectives are met.

Ribo Life Science boasts a fully integrated research and development (R&D) platform, underpinned by robust intellectual property rights. Notably, its innovative delivery technology, RiboGalSTARTM, is already pushing several products into Phase II clinical trials. The company has established R&D centers strategically located in Suzhou, Beijing, and Gothenburg, Sweden, enhancing its capability for end-to-end drug development that spans from discovery to global clinical trials.

As part of the IPO process, Ribo Life Science received professional underwriting support from China International Capital Corporation and Citigroup, which played instrumental roles in facilitating the company’s successful entry into the capital markets.

About Ribo Life Science

Founded in Suzhou, Ribo Life Science Co., Ltd. is a global leader in biopharmaceutical development, focusing on the advancement and commercialization of siRNA therapeutics. Utilizing its proprietary and innovative technology platforms, the company has cultivated a rich pipeline that targets several critical disease areas, including cardiovascular, metabolic, liver, and kidney diseases. Ribo is dedicated to delivering groundbreaking treatments to patients around the world through continuous innovation and development, maintaining a commitment to creating sustainable value for its shareholders.

For more information on Ribo Life Science and its innovative pipeline, please visit www.ribolia.com.